BRCA1/2 Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data Study

Lieke Lanjouw,Joost Bart,Marian J. E. Mourits,Stefan M. Willems,Annemieke H. van der Hout,Arja ter Elst,Geertruida H. de Bock
DOI: https://doi.org/10.3390/cancers16091682
2024-04-27
Cancers
Abstract:Analyzing BRCA1/2 tumor pathogenic variants (TPVs) in epithelial tubal/ovarian cancers (EOCs) has become an essential part of the diagnostic workflow in many centers to guide treatment options and genetic cascade testing. However, there is no standardization of testing procedures, including techniques, gene assays, or sequencers used, and data on the execution of tumor tests remains scarce. Therefore, we evaluated characteristics of BRCA1/2 tumor testing in advanced-stage EOC with real-world national data. Pathology reports of patients diagnosed with EOC in 2019 in the Netherlands were obtained from the Dutch Pathology Registry (PALGA), and data regarding histological subtype and BRCA1/2 tumor tests were extracted. A total of 999 patients with advanced-stage EOC were included. Tumor tests were performed for 502 patients (50.2%) and BRCA1/2 TPVs were detected in 14.7%. Of all tests, 48.6% used hybrid capture techniques and 26.5% used PCR-based techniques. More than half of the tests (55.0%) analyzed other genes in addition to BRCA1/2. Overall, this study highlights the heterogeneity in the execution of BRCA1/2 tumor tests. Despite a lack of evidence of quality differences, we emphasize that adequate reporting and internal and external quality monitors are essential for the high-quality implementation and execution of reliable BRCA1/2 tumor testing, which is crucial for identifying all patients with BRCA1/2 TPVs.
oncology
What problem does this paper attempt to address?
The paper attempts to address the issues of standardization and quality control in the detection of BRCA1/2 gene pathological variants (TPVs) in patients with ovarian cancer (EOC). Specifically: - **Research Background**: Currently, DNA analysis of tumor cells from patients with epithelial tubal/ovarian cancer (EOC) is performed in multiple medical centers to detect pathological variants (TPVs) in the BRCA1/2 genes. This information is crucial for guiding treatment plans and further genetic testing. However, the detection procedures lack standardization, and there is limited information about the detection methods. - **Research Objective**: Using real clinical data from 2019 across the Netherlands, the study describes the specific implementation of BRCA1/2 tumor testing in 999 EOC patients. The results show that 50.2% of the patients underwent tumor testing, with 14.7% of the tests identifying TPVs. Additionally, the study found significant differences in the detection techniques and gene testing panels used by different laboratories. - **Main Findings**: Although there is no evidence of significant differences in detection quality, the study emphasizes the importance of reporting standards and internal and external quality control to ensure that all centers can reliably perform BRCA1/2 tumor testing, thereby identifying all patients carrying BRCA1/2 TPVs. Overall, this paper aims to reveal the heterogeneity and lack of standardization in current BRCA1/2 tumor testing and highlights the necessity for improved reporting and quality control.